Bioretec Ltd Press release 16 May 2023 at 10:00 a.m. EEST TAMPERE, Finland, May 16, 2023 /PRNewswire/ — Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company’s U.S. commercialization strategy from a clinical and regulatory perspective. Dr. Dublon joins the Bioretec team as a … Read more
Bioretec Ltd Press release 16 May 2023 at 10:00 a.m. EEST TAMPERE, Finland, May 16, 2023 /PRNewswire/ — Bioretec Ltd, a pioneer in bioresorbable orthopedic implants, announces that Dr. Jeremy Dublon joins the Bioretec team to support Company’s U.S. commercialization strategy from a clinical and regulatory perspective. Dr. Dublon joins the Bioretec team as a … Read more
TEL AVIV, Israël, 16 mai 2023 /PRNewswire/ — iMDsoft, leader mondial des systèmes d’information clinique et développeur de la suite MetaVision™ pour les soins intensifs, l’anesthésie et les soins aigus, a annoncé aujourd’hui son partenariat avec RespiratoryCareAfrica (Pty) Ltd (RCA) pour le marché sud-africain. Dans le cadre de ce partenariat, RCA sera autorisé à commercialiser … Read more
HELSINKI, May 16, 2023 /PRNewswire/ — Askel Healthcare, the Finnish medical technology company offering a new method for the treatment of knee cartilage damage, has started a fundraising campaign to raise up to 5 million euros to finance clinical trials of its COPLA® implant. The public phase of the ongoing fundraising campaign started today and closes on … Read more
VADUZ, Liechtenstein, May 16, 2023 /PRNewswire/ — Implantica AG (publ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dr. med. Zehetner, Prof. (USC) from Switzerland, presented Klinik Beau-Site’s RefluxStop™ results at Digestive Disease Week (DDW) 6-9 May, in Chicago, U.S., the world’s premier meeting for gastrointestinal professionals Dr. med. … Read more
– Conduct collaborative research on Sony’s unique polymeric materials to achieve high-DAR ADC – TOKYO, May 16, 2023 /PRNewswire/ — Sony Corporation (President and CEO: Kimio Maki, “Sony”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that they have entered into a collaborative research agreement to discover a novel Antibody-Drug Conjugate (ADC)*1 … Read more
STOCKHOLM, May 16, 2023 /PRNewswire/ — Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout “In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning … Read more
STOCKHOLM, May 16, 2023 /PRNewswire/ — Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout “In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning … Read more
Accelerating Research and Development, and Access and Delivery for NTDs TOKYO, May 16, 2023 /PRNewswire/ — On May 12th, the eve of the G7 Health Ministers’ Meeting, global health leaders from around the world convened in Nagasaki to call for the prioritization of neglected tropical diseases (NTDs). Gathering at the Symposium for G7 Health Ministers’ … Read more
STOCKHOLM, May 16, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril[1] antibody, for the treatment of early Alzheimer’s disease[2] with confirmed amyloid pathology in the brain. … Read more